<DOC>
	<DOCNO>NCT02372162</DOCNO>
	<brief_summary>This single center , open-label , uncontrolled , non-randomized observational study patient advance HCC . The patient qualify either local treatment transarterial chemoembolization ( TACE ) systemic treatment multikinase inhibitor sorafenib . The aim feasibility study get comprehensive image molecular fingerprint individual tumor , intention govern therapy decision . Furthermore , improve care patient get progressive disease treatment , investigator improve investigator understand development therapy resistance , improve patient care time point progressive disease . Therefore , data 20 patient group use identify molecular / image pattern , use predict treatment response thus govern optimize individual cancer treatment patient advance HCC .</brief_summary>
	<brief_title>Fingerprint Characterization Advanced HCC</brief_title>
	<detailed_description>A single-center , open-label , uncontrolled , non-randomized clinical trial . The two treatment group receive : Group A Transarterial Chemoembolization ( TACE ) : 20 patient treat TACE get image molecular fingerprint tumor prior first treatment TACE , second image fingerprint week 2 - 4 first treatment TACE , third image molecular fingerprint time point progressive disease . Group B Sorafenib : 20 patient treat Sorafenib get image molecular fingerprint tumor prior first treatment , week 2 3 start treatment time point progressive disease .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>All inclusion criterion must meet time screen unless otherwise specify : 1 . Male female ≥ 18 year . 2 . Written inform consent obtain prior trial specific procedure . 3 . Advanced stage hepatocellular carcinoma , BCLC class B Group A BCLC class B C Group B ( refer Appendix 3 BCLC classification ) . 4 . ChildPugh class A B . Only patient ChildPugh index class B 7 include . Patients untreatable ascites hepatic encephalopathy &gt; Grade 1 exclude ( see exclusion criterion ; ( refer Appendix 4 Child Pugh classification ) ) . 5 . Indication TACE sorafenib treatment confirm interdisciplinary tumor board . 6 . ECOG performance status 0 , 1 2 ( refer Appendix 2 definition ECOG grade ) . 7 . Life expectancy 12 week . 8 . Adequate hematological parameter , demonstrate : Hemoglobin ≥ 9.0 g/dl ( SI unit : 5.6 mmol/l ) ; WBC ≥ 3.0 x 109/l ; Absolute neutrophil count ≥1,500/mm3 ; Platelets ≥ 75 x 109/l ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 5 time upper limit normal range ( ULNR ) ; Bilirubin ≤ 3 mg/dl ; Serum creatinine ≤ 1.5 mg/dl ( SI unit : 132 µmol/l ) ; Prothrombin Time ( PT ) International Normalized Ratio ( INR ) ≤ 1,5 ; Serum potassium , magnesium calcium within normal range . 9 . Safe contraception female childbearing potential entire study use establish treatment hormonal contraceptive least 2 month prior start screen . 10 . For female child bear potential ( without use hormonal contraceptive least 2 month prior start screen ) double contraception method request entire study meeting criterion effective method birth control . That mean least two effective birth control method condom , diaphragm intrauterine device must use . 11 . Male patient partner child bear potential request use barrier contraception addition partner use another method contraception trial 3 month last dose . Male patient also advise abstain sexual intercourse pregnant lactate woman , use condom . 12 . Able comply requirement protocol . Patients meet follow criterion eligible study participation : 1 . Renal failure require hemo peritoneal dialysis . 2 . Known central nervous system ( CNS ) tumor include symptomatic brain metastasis . 3 . Patients adequate treatment gastrointestinal bleeding esophagus varix within 14 day prior study entry . 4 . ChildPugh index class B combination slight ascites hepatic encephalopathy &gt; Grade I ( see ChildPugh index , Appendix 4 ) . 5 . History current cardiovascular complication , include unstable angina pectoris , uncontrolled hypertension , congestive heart failure ( NYHA Class III IV ) relate primary cardiac disease , condition require anti arrhythmic therapy , ischemic severe valvular heart disease , myocardial infarction within 6 month prior trial entry . 6 . Current evidence severe internal , psychiatric neurologic disease . 7 . Altered mental status preclude understand informed consent process and/or completion necessary study . 8 . Pregnant breastfeed woman . 9 . Active alcohol and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Molecular Diagnostics</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Therapeutic chemoembolization</keyword>
	<keyword>Next-generation sequencing</keyword>
	<keyword>Sequence analysis , DNA</keyword>
	<keyword>Sequence analysis , RNA</keyword>
	<keyword>Metabolomics</keyword>
</DOC>